Back

Risk of death and thromboembolic events in patients with supraventricular arrhythmias admitted to the emergency department.

9 April 2024 (08:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Poster session on ventricular tachycardia, others Clinical EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Tommaso Bucci

University of Perugia, Perugia (Italy)

105 More presentations in this session

Presentation thumbnail
Clinical accuracy of a 3-dimensional multielectrode non-invasive ECG mapping vest in premature ventricular contraction ablation procedures
Associate Professor B. Hunuk (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia. A retrospective analysis and optimisation of the planning phase.
Mr J. Solana Munoz (Lausanne, CH)
Abstract
Presentation thumbnail
Electrophysiological characteristics of tachyarrhythmia and effects of catheter ablation in patients with Fontan circulation
Assistant Professor J. Uhm (Seoul, KR)
Abstract
Presentation thumbnail
Accuracy of pace-mapping using an automated template matching module for site of origin identification of idiopathic outflow tract premature ventricular contractions
Doctor N. Schaerli (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Epicardial catheter ablation of ventricular tachycardia in patients of acm - from a university hospital report in switzerland
Doctor F. Guan (Zurich, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session on ventricular tachycardia, others

The Event

Event poster

EHRA 2024

9 April 2024 08:00 CET
You may be interested in
thumbnail
Congress Session
Registries on atrial fibrillation and sudden death
thumbnail
Congress Presentation
Real world data on SVT ablation in Denmark Higher risk of need for reablation in todays patient population a Nationwide registry based Danish study
thumbnail
Congress Presentation
Incidence, management and outcomes of patients with incident atrial fibrillation in the contemporary direct oral anti coagulants era. A national study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources